Valuation: Positron Corporation

Market Cap 56.49M 48.79M 45.91M 41.73M 78.48M 5.41B 79.63M 539M 211M 2.71B 212M 208M 9.02B P/E 2024
-11x
P/E 2025 -4.87x
Enterprise Value 55.36M 47.81M 44.99M 40.89M 76.9M 5.3B 78.03M 528M 207M 2.65B 208M 203M 8.84B EV / Sales 2024
49.4x
EV / Sales 2025 116x
Free-Float
45.36%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
President 53 2018-02-26
Sales & Marketing - 2022-06-23
Corporate Officer/Principal 40 2018-05-24
Director TitleAgeSince
Chairman 53 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+2.50%+74.47% - - 56.49M
+1.27%-3.13%-14.68%-17.72% 13.11B
+0.45%+10.77%+47.27%+18.08% 4.64B
-1.27%-0.78%-41.05%-52.57% 1.3B
-5.57%+14.91%-36.04% - 1.2B
-0.79%-1.82%-35.72%-38.35% 1.19B
-0.47%-1.41%+25.07%+84.76% 1.13B
-3.86%-7.20%+37.25%+134.70% 595M
-3.65%-5.30%+56.25% - 323M
+2.39%-1.93%-61.81%+281.50% 253M
Average -0.88%-2.59%-2.61%+58.63% 2.64B
Weighted average by Cap. +0.26%-0.34%-2.49%-0.70%

Financials

2024 2025
Net sales 588K 507K 477K 434K 816K 56.29M 828K 5.6M 2.19M 28.15M 2.21M 2.16M 93.77M 461K 399K 375K 341K 641K 44.21M 650K 4.4M 1.72M 22.11M 1.73M 1.69M 73.66M
Net income -2.38M -2.05M -1.93M -1.76M -3.3M -228M -3.35M -22.68M -8.89M -114M -8.93M -8.74M -380M -10.6M -9.16M -8.62M -7.83M -14.73M -1.02B -14.95M -101M -39.61M -508M -39.81M -38.95M -1.69B
Net Debt 1.42M 1.23M 1.16M 1.05M 1.98M 136M 2.01M 13.58M 5.32M 68.26M 5.35M 5.23M 227M -1.14M -981K -923K -839K -1.58M -109M -1.6M -10.83M -4.24M -54.45M -4.27M -4.17M -181M
Logo Positron Corporation
Positron Corporation is a medical technology company focused to advancing the Positron Emission Tomography (PET) imaging modality through the development, manufacturing, and commercialization of its PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems along with providing comprehensive clinical services to nuclear medicine healthcare providers across North America. The Company specializes in the field of cardiac PET imaging, the gold standard in cardiac diagnostics. The Company’s imaging portfolio includes dedicated PET and 3D PET-CT 64-Slice systems, both designed to expand access to advanced molecular imaging. Additionally, it is preparing to introduce its 4D PET-CT 64-Slice scanner in nuclear cardiology. Its products, Attrius PET and NeuSight PET-CT 64- Slice scanner, provide a molecular imaging solution, enabling healthcare providers with diagnostic accuracy for cardiac and oncologic applications.
Employees
-